Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (141-150 of 430) with videos related to

Pageof 43
Sort By:
Cancer Treatment Reports|July 1, 1985
Continuous infusion of vinblastine for advanced hormone-refractory prostate cancerF Dexeus, C J Logothetis, M L Samuels, et al.
Frontiers in Oncology|March 31, 2018
Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate CancersRama Soundararajan, Ana M Aparicio, Christopher J Logothetis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trialK Fizazi, K A Do, X Wang, et al.
The Journal of Urology|October 1, 1994
Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinomaD Mitropoulos, M A Dimopoulos, A Kiroudi-Voulgari, et al.
Yonsei Medical Journal|May 20, 1999
Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic eraD S Park, D M Prow, R J Amato, et al.
Cancer Treatment Reports|January 1, 1982
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary reportC J Logothetis, A C von Eschenbach, M L Samuels, et al.
British Journal of Cancer|April 3, 1999
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitorJ Horti, S C Dixon, C J Logothetis, et al.
The Journal of Urology|May 1, 1995
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancerD D Daliani, P D Eisenberg, J Weems, et al.
Expert Opinion on Investigational Drugs|November 1, 2011
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trialsAndreas Varkaris, Paul G Corn, Sanchaika Gaur, et al.
The Journal of Urology|October 1, 1987
Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patientsC J Logothetis, M L Samuels, S L Ogden, et al.
Pageof 43

Showing results (141-150 of 430) with videos related to

Sort By:
Pageof 43
Cancer Treatment Reports|July 1, 1985
Continuous infusion of vinblastine for advanced hormone-refractory prostate cancerF Dexeus, C J Logothetis, M L Samuels, et al.
Frontiers in Oncology|March 31, 2018
Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate CancersRama Soundararajan, Ana M Aparicio, Christopher J Logothetis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trialK Fizazi, K A Do, X Wang, et al.
The Journal of Urology|October 1, 1994
Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinomaD Mitropoulos, M A Dimopoulos, A Kiroudi-Voulgari, et al.
Yonsei Medical Journal|May 20, 1999
Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic eraD S Park, D M Prow, R J Amato, et al.
Cancer Treatment Reports|January 1, 1982
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary reportC J Logothetis, A C von Eschenbach, M L Samuels, et al.
British Journal of Cancer|April 3, 1999
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitorJ Horti, S C Dixon, C J Logothetis, et al.
The Journal of Urology|May 1, 1995
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancerD D Daliani, P D Eisenberg, J Weems, et al.
Expert Opinion on Investigational Drugs|November 1, 2011
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trialsAndreas Varkaris, Paul G Corn, Sanchaika Gaur, et al.
The Journal of Urology|October 1, 1987
Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patientsC J Logothetis, M L Samuels, S L Ogden, et al.
Pageof 43